The pathway ahead in melanoma trials.
Miller
Arlo J
AJ
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
Markovic
Svetomir N
SN
Haluska
Paul
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D051358:Cyclin-Dependent Kinase 4 / Q000235:genetics; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D019942:Genes, p16; D006801:Humans; D008545:Melanoma / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D009389:Neovascularization, Pathologic; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics
D020533:Angiogenesis Inhibitors; D019941:Cyclin-Dependent Kinase Inhibitor p16; D042461:Vascular Endothelial Growth Factor A; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D051358:Cyclin-Dependent Kinase 4; D018631:ras Proteins